AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Polypeptide N-acetylgalactosaminyltransferase 12

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8IXK2

UPID:

GLT12_HUMAN

Alternative names:

Polypeptide GalNAc transferase 12; Protein-UDP acetylgalactosaminyltransferase 12; UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 12

Alternative UPACC:

Q8IXK2; Q5TCF7; Q8NG54; Q96CT9; Q9H771

Background:

Polypeptide N-acetylgalactosaminyltransferase 12, also known as GALNT12, plays a pivotal role in the biosynthesis of mucin-type oligosaccharides in digestive organs. It catalyzes the transfer of N-acetyl-D-galactosamine to serine or threonine residues on protein receptors, crucial for the initial step of mucin-type oligosaccharide biosynthesis. GALNT12 shows specificity towards non-glycosylated peptides, indicating its selective role in cellular processes.

Therapeutic significance:

GALNT12's involvement in colorectal cancer underscores its potential as a therapeutic target. Although its role in cancer susceptibility is debated, understanding GALNT12's function could lead to novel strategies for colorectal cancer prevention and treatment, highlighting the importance of further research in this area.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.